TSE:MFC

Manulife Financial (MFC.TO)

57.04
+0.49 (0.87%)
as of Jun 25, 2026, 8:00:00 pm Market Open.
1634 watching
0
Investor Insights
star iconJun 25, 2026, 12:00 am

This summary was created by AI, based on 28 opinions in the last 12 months.

Manulife Financial (MFC) has garnered mixed opinions from market experts. Many analysts recognize MFC's potential, particularly highlighting its growth in Asia and successful capital generation from legacy businesses. The consensus seems to indicate a solid long-term investment due to its steady dividend yield, with several experts suggesting that patience may be required as the stock navigates short-term fluctuations. Despite some concerns about past performance and market positioning against competitors, the company's strategy and management is viewed positively. Analysts mention the current valuation as reasonable compared to peers, suggesting MFC is a better option for income rather than growth. Overall, there is a cautious optimism about MFC's capabilities and future direction.

consensus icon
Consensus
Hold
valuation icon
Valuation
Fair Value
review icon
Similar
SLF-T
PAST TOP PICK
(A Top Pick Jan 23/18, Down 20%) A disappointment, but so have all the insurers. Trading at a "buy" valuation. Would buy for new clients. Manulife is exposed to Asian economy, which is slowing, so there may be an opportunity to buy when the fourth quarter reports. Extremely well capitalized. May see disposal of assets. Lots of strength going forward.
BUY
He has a target price of $31 on it. It is frustrating. There are fears for their business with China; fears of higher interest rates; fears of MFC-T changing it policy. When you build a fortress balance sheet your growth comes down. Eventually the market will catch on to its strong points. 5% yield vs. 4.4% on SLF-T as it has a higher perceived risk, being stuck in Canada.
DON'T BUY
At the bottom of his list. Insurers are hard to analyze. Only ones they ever own are Berkshire Hathaway and Markel. Leaves this to smarter investors. Management has done a great job trying to diversify.
BUY ON WEAKNESS
He thinks it is superb value. His models shows 200% upside potential. Has a nice dividend yield well covered. Despite all this the stock is falling giving him a short term sell technically reaching $16. He likes the stock fundamentally but technically not. All insurance companies look like this.
PAST TOP PICK
(A Top Pick Nov 02/17, Down 27%) All insurers have pulled back because interest rates won't rise as much as expected. Down to 9x earnings with a 5% yield. Valuations are now stunningly low. MFC has Asian operations, but the stock isn't down because of that. It won't stay down at this price.
WEAK BUY
He bought a couple of weeks ago. 8 times core operating earnings. The balance sheet is in better shape. They fixed a lot of their problems and you still have growth in Asia. There is still financial market risk.
DON'T BUY
He thinks financials are facing challenged with rising interest rates. There has been a recent bearish technical analysis, making him overall cautious on the stock. He would not be a buyer at this time.
WEAK BUY
The lifecos in Canada have not done well this year. We saw a breakdown in this one this month. We see rising rates and this should help MFC-T. We have seen a substantial pull down in MFC-T and it tends to do well until April each year.
COMMENT
General opinion of the sector The insurance group had run up earlier in the year as longer term interest rates were expected to rise. However, as short term rates have risen faster this has taken the wind out of the sails. There is still more upside in rates and with yields of 5%, it is a good long term holding. The MFC-T lawsuit over long term contracts will create uncertainty.
PAST TOP PICK
(A Top Pick Sep 26/18, Down 20%) Bought it as an oversold candidate. It's broken down like other stocks. "Old support becomes new resistance," so when stock returns, people start selling.
BUY
Increased their dividend by 20% this year, now above 5%. Interest rates went up--then down, which hurt the lifecos, MFC is doing a good job of selling their legacy businesses, which improves their outlook. Their traditional cash flow out of their Canadian business creates cash flow, and their Asian operation is good especially for long-term.
BUY
The lifecos are attractive after this correction. Solid businesses. SLF has a big U.S. asset management operation. But she prefers (and owns) MFC which has a better valuation. In the past. SLF's earnings have outgrown MFC's, but MFC's should outpace SLF's going forward. MFC trades at a discount to SLF.
BUY
It has probably been hit the hardest because of legacy issues, mostly that have been addressed now.
BUY
Still a buy despite the legal challenge? He lends no credence to this case. Any court will side with MFC, given the law. The case is not a headwind--look past it. MFC is very well-managed. They've turned around since cutting their dividend during the Recession a decade ago.
DON'T BUY
The chart for this stock doesn't look too attractive. Valuations seems relatively cheap but he prefers to wait until sentiment improves.
Showing 436 to 450 of 2,281 entries